Pharmacokinetics in Healthy Adult and Elderly Patients of ACP‐204, a Novel 5‐HT <sub>2A</sub> Receptor Selective Antagonist/Inverse Agonist
The PK profiles were qualitatively similar over the studied dose ranges in healthy elderly and adult participants with minimal difference in exposure parameters 14% and 20% for C<sub>max,ss</sub> and AUC <sub>τ</sub>, respectively. ACP-204 was generally safe and well tolerated across age groups, with no unexpected safety findings.
Authors
- Bryan Dirks (ORCID: https://orcid.org/0000-0001-6472-1606)
- Mona Darwish
- Sanjeev Pathak (ORCID: https://orcid.org/0000-0003-1565-2223)
- B. Raether
- Xiaoshu Feng
Institutions
- Acadia Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105732
- Primary Topic
- Nicotinic Acetylcholine Receptors Study
- Type
- article
- Field-Weighted Citation Impact
- 0.00